Gilead Touts Phase III Results for Liver Disease Drug Ahead of PDUFA Date
Pictured: Gilead corporate headquarters in Silicon Valley iStock/Sundry Photography Gilead Sciences announced Saturday that Seladelpar, part of the $4.3 billion purchase of CymaBay in February 2024, posted positive interim late-stage results in …